Vaxxas Employee Directory

Vaxxas corporate office is located in 240 Macarthur Ave, Hamilton, Queensland, 4007, Australia and has 51-200 employees.

Employees by Department

Departments

Number of employees

Engineering & Technical

33

Operations

23

Information Technology

8

Finance

7

C-Suite

7

Medical & Health

5

Legal

4

Vaxxas CEO

David Peacock, Chief Executive Officer at Vaxxas
Australia flag for contact location.
David PeacockChief Executive Officer
PhonePhoneEmailEmail
See Profile

Key Employees of Vaxxas

Vaxxas Global Presence

globalPresence illustration
Australia51-200
North America1-10

Index of contact profiles from Vaxxas

Hundreds of professionals searching for Vaxxas have connected with key decision-makers. Join them?
Contact Name
Contact Info
Job Title
HQ Location
1234

Former Employees at Vaxxas

Explore people who held key positions, contributed to Vaxxas's success, and advanced their careers.

People from Similar Companies in the Manufacturing Industry Located in Australia

Frequently Asked Questions Regarding Vaxxas Employees

How many employees does Vaxxas have?
Vaxxas has 51-200 employees
Who is the CEO of Vaxxas?
Vaxxas’s CEO is David Peacock
Who is the CFO of Vaxxas?
Vaxxas’s CFO is Helen Liu
Who are Vaxxas key employees?
Some of Vaxxas key employees are Helen Liu, Angus Forster, Douglas Cubbin, Scott Fry
Where is Vaxxas located?
Vaxxas’s headquarters are located at 240 Macarthur Ave, Hamilton, Queensland, 4007, Australia
How do I contact Vaxxas?
Vaxxas Contact Info: Website: www.vaxxas.com
What does Vaxxas do?

Vaxxas is a clinical-stage private biotechnology company pioneering its proprietary high-density microarray patch (HD-MAP) for needle-free vaccine delivery. The HD-MAP has been administered to more than 750 participants across multiple clinical trials, showing strong safety, tolerability, and robust immune responses. Preclinical and clinical data d... emonstrate the technologys ability to deliver all major vaccine modality types including live attenuated, protein subunit, and mRNA positioning the platform as a universal delivery solution. By targeting immune cells just beneath the skin, the HD-MAP can achieve stronger protection with smaller doses, while reducing cold-chain requirements and enabling self-administration. With the potential to disrupt the multibillion-dollar global vaccine market by improving access, reducing costs, and expanding coverage, Vaxxas is now scaling manufacturing and advancing its lead programs toward commercialisation from its base in Brisbane, AustraliaRead More

Is Vaxxas a public company?
Vaxxas is private company therefore does not currently have an official ticker symbol
See more information about Vaxxas Employees

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.